Home » Newsletters » BioWorld

BioWorld

May 25, 2006

View Archived Issues

Sirna Brings In $45M Publicly; Lead Drug Aimed For Phase II

Sirna Therapeutics Inc. bolstered its bank account with a $45 million financing that closed Wednesday. (BioWorld Today) Read More

CareX Purchase Expands 7TM's Early Stage Metabolic Pipeline

Ocera's AST-120 In Phase III Trial For Fistulizing Crohn's

Aphton Bankruptcy News Blasts Stock; Igeneon Also Facing Risk

Other News To Note

Appointments And Advancements

Clinic Roundup